SCHEMBL9607635

SCHEMBL9607635

COc1c(-c2ccc(C)cc2)ncnc1-c1ccc2c(c1)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.39
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
PDE5A O76074 1/20 0.38
KMO O15229 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
EGFR P00533 2/20 0.38
LCK P06239 2/20 0.38
ALOX12 P18054 1/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
POLB P06746 1/20 0.37
ADCY8 P40145 1/20 0.36
ADCY1 Q08828 1/20 0.36
SCN9A Q15858 1/20 0.35
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6919052 0.72 HDAC1 (0.43) KIT
SCHEMBL6918405 0.71 KMO (0.43) MAPTKMOSMN1; SMN2EGFRNPC1
SCHEMBL5905931 0.69 CYP11B1 (0.50) HPGDMAPTSMN1; SMN2ALOX12NPC1
SCHEMBL31442483 0.69 NR4A2 (0.44) HPGDMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL25796997 0.69 NR4A2 (0.44) HPGDMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL18650301 0.67 ALDH1A1 (0.49) KITHPGDMAPTSMN1; SMN2EGFR
SCHEMBL9607736 0.67 ADORA1 (0.51) EGFRNPC1RAB9APOLBLMNA
SCHEMBL30042627 0.66 CYP11B1 (0.47) HPGDMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL414198 0.65 NPC1 (0.52) HPGDMAPTSMN1; SMN2ALOX12NPC1
SCHEMBL6918147 0.65 F9 (0.46) HPGDMAPTKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 KIT 762/4885HPGD 517/4885MAPT 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.